Premium
Targeted nanomedicines for the treatment of bone disease and regeneration
Author(s) -
Ordikhani Farideh,
Zandi Nooshin,
Mazaheri Mozhdeh,
Luther Gaurav A.,
Ghovvati Mahsa,
Akbarzadeh Abolfazl,
Annabi Nasim
Publication year - 2021
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21759
Subject(s) - nanocarriers , nanomedicine , medicine , drug delivery , targeted drug delivery , osteoporosis , multiple myeloma , drug , bone disease , pharmacology , nanotechnology , materials science , nanoparticle
Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone‐targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.